Evidence map›Paper›PMID 40132830›Full record

ArticleBMJ open2025

Investigation of ethics approval as part of a research integrity assessment of randomised controlled trials in COVID-19 evidence syntheses: a meta-epidemiological study.

Florencia Weber, Tamara Pscheidl, Emma Sydenham, Patrick Meybohm, Stephanie Weibel

Abstract read
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Florencia WeberIntensive Care, Emergency and Pain Medicine, Department of Anaesthesiology, University Hospital Würzburg, Würzburg, Germany.
Tamara PscheidlIntensive Care, Emergency and Pain Medicine, Department of Anaesthesiology, University Hospital Würzburg, Würzburg, Germany.
Emma SydenhamCochrane Central Editorial Service, Cochrane, London, UK.ORCID http://orcid.org/0000-0002-1471-4237
Patrick MeybohmIntensive Care, Emergency and Pain Medicine, Department of Anaesthesiology, University Hospital Würzburg, Würzburg, Germany.ORCID http://orcid.org/0000-0002-2666-8696
Stephanie WeibelIntensive Care, Emergency and Pain Medicine, Department of Anaesthesiology, University Hospital Würzburg, Würzburg, Germany weibel_s@ukw.de.ORCID http://orcid.org/0000-0003-1900-2535

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesEthical compliance of randomised controlled trials (RCTs) documented as ethics committee (EC) approval is vital for participant protection but is often overlooked by evidence synthesis producers despite regulatory mandates. We aimed to systematically assess reporting of ethics approval and informed consent (IC) in RCTs included in evidence syntheses and examined its potential impact on the study pool as part of a research integrity assessment (RIA).

designMeta-epidemiological study.

settingAssessment of ethics approval; domain 3 of the RIA tool developed for evidence syntheses. PARTICIPANTS/SUBJECTS: COVID-19 RCTs included in evidence syntheses. PRIMARY OUTCOMES: We extracted ethical items from study reports, that is, ethics approval statements, EC details, ethics approval numbers (ENs), IC and verified national recognition of ECs. RCTs were assessed regarding ethics approval and categorised as 'no concern', 'awaiting classification' or 'exclude' from the study pool. We also examined the impact of study settings on ethics approval reporting and discussed assessment reliability.

resultsWe included 188 RCTs. 93% of primary study reports contained an ethics statement, 70% provided EC details, 44% reported EN and 91% mentioned IC. Trial registration records identified the EC in 8 RCTs and EN in 25 RCTs. Overall, 41% of RCTs reported all ethical items. Authors of 95 RCTs were contacted for missing information, yielding 22 satisfactory responses. Of the 151 RCTs with identified ECs, 88% were nationally recognised. Overall, 53% of RCTs were classified as 'no concern', 47% as 'awaiting classification' and none were excluded. Most were 'awaiting classification' due to reporting-related reasons. No significant differences in ethics approval reporting were observed across study settings, countries, or sample sizes.

conclusionsReporting of ethical items in RCTs remains inadequate. Including ethics approval details in reporting guidelines such as Consolidated Standards of Reporting Trials could improve this. Current under-reporting issues limit the reliability of the RIA tool's ethics approval assessment. PROTOCOL REGISTRATION: The protocol is available on OSF (https://osf.io/3bzeg).

Indexed as

COVID-19Ethics Committees, ResearchRandomized Controlled Trials as TopicHumansInformed ConsentSARS-CoV-2MEDICAL ETHICSSTATISTICS & RESEARCH METHODSSystematic Review

Identifiers

PMID40132830
PMCPMC11934354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.